Table 1

Baseline characteristics of 30 patients with very early inflammatory back pain

Mean (SD) age (years)31.1 (5.4)
Men, n (%)15 (50)
Median (IQR), (range) BMI (kg/m2)23.3 (4.2), (19.2–35.9)
Median (IQR), (range) disease duration (weeks)24 (38), (2–260)
HLA-B27 positive, n (%)17 (56.7)
Median (IQR), (range) back pain during day on VAS55.0 (34.0), (0–95)
Median (IQR), (range) back pain during night on VAS60 (44), (0–100)
Mean (SD) BASDAI6.22 (2.07)
Mean (SD) BASFI4.81 (2.64)
Median (IQR), (range) CRP (mg/l)10 (17), (5–65)
Patients on NSAIDs, n (%)24 (80)
Presence of BMO on SIJ
MRI
 Median (IQR), (range) MRI BMO SIJs (range for MRI scoring method 0–24)3.0 (8), (0–19)
 Presence of BMO on MRI SIJs, n (%)29 (96.7)
 Presence of BMO on MRI lumbar spine, n (%)5 (16.7)
BMD (g/cm2)
 Mean (SD) femoral necks1.03 (0.13)
 Mean (SD) total hips1.06 (0.13)
 Mean (SD) spine L2–41.24 (0.15)
 Mean (SD) hands0.45 (0.05)
T-score
 Mean (SD femoral necks0.06 (1.08)
 Mean (SD) total hips0.13 (1.05)
 Mean (SD) spine L2–40.18 (1.29)
  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Disease Functional Index; BMD, bone mineral density; BMI, body mass index; BMO, bone marrow oedema; CRP, C-reactive protein; HLA-B27, human leucocyte antigen B27; NSAIDs, non-steroidal anti-inflammatory drugs; SIJs, sacroiliac joints; VAS, visual analogue scale (0–100 mm).